Tapinarof cream 1% in plaque psoriasis: a profile of its use

Tapinarof (VTAMA®) cream 1%, a topical, non‐steroidal, aryl hydrocarbon receptor agonist, presents a valuable addition to the therapy options for topical treatment of plaque psoriasis in adults. In the pivotal 12‐week, randomized, double‐blind, vehicle‐controlled, phase 3 PSOARING 1 and PSOARING 2 trials, once‐daily tapinarof cream 1% was shown to be efficacious in reducing the severity of plaque psoriasis. Furthermore, evidence from an open‐label extension study shows that continuous and intermittent use of tapinarof cream 1% for up to 1 year has durable on‐treatment efficacy with a substantial remittive effect off treatment. Tapinarof cream 1% was generally well tolerated, with few patients discontinuing treatment in the pivotal trials due to adverse events, and with no new safety signals identified with longer‐term treatment. Post‐marketing real‐world data and/or active‐controlled studies to compare tapinarof cream 1% with other topical treatments used for plaque psoriasis would be of interest.